Hangzhou Tigermed Consulting Co., Ltd. Class H Statistics
Want to see HK:3347 full AI Analyst Report?
Hangzhou Tigermed Consulting Co., Ltd. Class H (3347) Stock Statistics & Valuation Metrics
Total Valuation
Hangzhou Tigermed Consulting Co., Ltd. Class H has a market cap or net worth of HKD 39.88B. The enterprise value is HKD 43.47B.
- Market Cap
- HKD 39.88B
- Enterprise Value
- HKD 43.47B
Share Statistics
Hangzhou Tigermed Consulting Co., Ltd. Class H has 123,124,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 123,124,800
- Owned by Insiders
- ―
- Owned by Institutions
- 15.43%
Financial Efficiency
Hangzhou Tigermed Consulting Co., Ltd. Class H’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 3.11%.
- Return on Equity (ROE)
- 0.04
- Return on Assets (ROA)
- 0.03
- Return on Invested Capital (ROIC)
- 3.11%
- Return on Capital Employed (ROCE)
- 0.04
- Revenue Per Employee
- 613.91K
- Profits Per Employee
- 79.77K
- Employee Count
- 11,130
- Asset Turnover
- 0.24
- Inventory Turnover
- 119.50
Valuation Ratios
The current PE Ratio of Hangzhou Tigermed Consulting Co., Ltd. Class H is -97.83. Hangzhou Tigermed Consulting Co., Ltd. Class H’s PEG ratio is 0.58.
- PE Ratio
- -97.83
- PS Ratio
- 4.52
- PB Ratio
- 1.99
- Price to FCF
- 30.97
- Price to Operating Cash Flow
- 30.56
- PEG Ratio
- 0.58
Income Statement
In the last 12 months, Hangzhou Tigermed Consulting Co., Ltd. Class H had revenue of 6.83B and earned 887.89M in profits. Earnings per share was 1.03.
- Revenue
- 6.83B
- Gross Profit
- 1.87B
- Operating Income
- 1.01B
- Pretax Income
- 1.00B
- Net Income
- 887.89M
- EBITDA
- 1.42B
- Earnings Per Share (EPS)
- 1.03
Cash Flow
In the last 12 months, operating cash flow was 1.29B and capital expenditures -172.68M, giving a free cash flow of 1.12B billion.
- Operating Cash Flow
- 1.29B
- Free Cash Flow
- 1.12B
- Free Cash Flow per Share
- 1.33
Dividends & Yields
Hangzhou Tigermed Consulting Co., Ltd. Class H pays an annual dividend of HKD 0.32, resulting in a dividend yield of 0.41%
- Dividend Per Share
- HKD 0.32
- Dividend Yield
- 0.41%
- Payout Ratio
- 41.18%
- Free Cash Flow Yield
- 3.17%
- Earnings Yield
- -1.01%
Stock Price Statistics
- Beta
- 1.02
- 52-Week Price Change
- -20.11%
- 50-Day Moving Average
- 42.09
- 200-Day Moving Average
- 39.94
- Relative Strength Index (RSI)
- 33.00
- Average Volume (3m)
- 1.47M
Important Dates
Hangzhou Tigermed Consulting Co., Ltd. Class H upcoming earnings date is Mar 29, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Mar 29, 2027
- Ex-Dividend Date
- Jun 12, 2025
Financial Position
Hangzhou Tigermed Consulting Co., Ltd. Class H as a current ratio of 2.18, with Debt / Equity ratio of 7.04%
- Current Ratio
- 2.18
- Quick Ratio
- 2.16
- Debt to Market Cap
- 0.03
- Net Debt to EBITDA
- -0.21
- Interest Coverage Ratio
- 11.15
Taxes
In the past 12 months, Hangzhou Tigermed Consulting Co., Ltd. Class H has paid 198.16M in taxes.
- Income Tax
- 198.16M
- Effective Tax Rate
- 0.20
Enterprise Valuation
Hangzhou Tigermed Consulting Co., Ltd. Class H EV to EBITDA ratio is 23.61, with an EV/FCF ratio of 31.52.
- EV to Sales
- 4.60
- EV to EBITDA
- 23.61
- EV to Free Cash Flow
- 31.52
- EV to Operating Cash Flow
- 27.29
Balance Sheet
Hangzhou Tigermed Consulting Co., Ltd. Class H has HKD 2.12B in cash and marketable securities with HKD 2.10B in debt, giving a net cash position of HKD 21.82M billion.
- Cash & Marketable Securities
- HKD 2.12B
- Total Debt
- HKD 2.10B
- Net Cash
- HKD 21.82M
- Net Cash Per Share
- HKD 0.18
- Tangible Book Value Per Share
- HKD 23.62
Margins
Gross margin is 25.80%, with operating margin of 8.58%, and net profit margin of -5.32%.
- Gross Margin
- 25.80%
- Operating Margin
- 8.58%
- Pretax Margin
- -2.76%
- Net Profit Margin
- -5.32%
- EBITDA Margin
- 19.50%
- EBIT Margin
- 15.90%
Analyst Forecast
The average price target for Hangzhou Tigermed Consulting Co., Ltd. Class H is HKD 49.90, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- HKD 49.90
- Price Target Upside
- 41.44% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- 21.72%
- EPS Growth Forecast
- -169.67%
Scores
- Smart Score
- 6
- AI Score
- 55

